US Patent

US11559501 — Transdermal amphetamine compositions with low levels of carbamate

Formulation · Assigned to Noven Pharmaceuticals Inc · Expires 2042-01-06 · 16y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods and compositions for reducing carbamate formation in transdermal amphetamine delivery systems.

USPTO Abstract

Described are methods for reducing the formation of amphetamine carbamate and amphetacarbamate in transdermal amphetamine compositions, compositions with low levels of amphetacarbamate, and methods using such compositions for transdermal delivery of amphetamine.

Drugs covered by this patent

dextroamphetamine (DEXTROAMPHETAMINE)

Patent Metadata

Patent number: US11559501
Jurisdiction: US
Classification: Formulation
Expires: 2042-01-06
Drug substance claim: No
Drug product claim: Yes
Assignee: Noven Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.